Opinion|Videos|April 25, 2025
Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines
Author(s)Alexandra K. Golant, MD
Alexandra Golant, MD discusses how the availability of topical ruxolitinib data in children as young as age 2 could potentially shift pediatric atopic dermatitis treatment guidelines by providing a non-steroidal alternative with a favorable safety profile.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- We now have data on topical ruxolitinib down to age 2. Do you think the introduction of topical JAK inhibitors for younger children could shift treatment guidelines for pediatric AD? Why or why not?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5
